We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 723

Three patent issues to watch in 2015

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • January 7 2015

Well, 2014 was a busy year in patent law, and it wasn't all good news for patent holders. The Supreme Court made 35 USC 101 a significant hurdle to

An early test for the USPTO’s eligibility analysis

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • December 21 2014

Just last week, the USPTO released its revised subject matter eligibility guidance (2014 Interim Guidance on Patent Subject Matter Eligibility

Federal Circuit invalidates Myriad primer and method claims as lacking subject matter eligibility

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • December 17 2014

In a case styled as In re BRCA1- and BRCA2-Based Hereditary Cancer Test Patent Litigation (also known as Myriad v. Ambry), the Federal Circuit held

Fetal diagnostics patent claims fall in inter partes review

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • December 16 2014

Post grant inter partes review proceedings have lowered the hurdle to invalidate U.S. patents. The "broadest reasonable construction" of the claims

USPTO releases revised subject matter eligibility guidance

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • December 16 2014

On December 15th, 2014, the USPTO released its much anticipated revised subject matter eligibility examination guidance to assist patent examiners

USPTO finally issues new guidance on patent subject matter eligibility

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • December 15 2014

The USPTO has issued new “Interim Guidance” for determining whether claims are eligible for patenting under 35 USC 101. Although the new guidance

Sequenom deal may avoid Federal Circuit decision

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • December 15 2014

Less than a month after their case was argued at the Federal Circuit, Illumina Inc. and Sequenom Inc. have announced a deal to settle their patent

Federal Circuit says secret prior art is prior art for all purposes

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • December 11 2014

In Tyco Healthcare Group LP v. Ethicon Endo-Surgery, Inc., the Federal Circuit agreed with the district court that Ethicon's prototype constituted

Another patent challenge for personalized medicine

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • December 8 2014

The U.S. Supreme Court's recent trilogy of patent-eligibility decisions (Prometheus, Myriadand Alice) have called into question the validity of many

Federal Circuit notes high burden of invoking inherency for obviousness

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • December 5 2014

In Par Pharmaceutical Inc. v. Twi Pharmaceuticals, Inc., the Federal Circuit vacated and remanded the district court decision holding the Par claims